1. Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third leading cause of cancer-related deaths. More than 80% of HCC cases are from the Asian and African continents, and more than 50% of cases are from mainland China. It is estimated that more than 50% of liver cancers worldwide are attributable to HBV and up to 89% of HBV-related HCC are from developing countries. Recently, increasing trends in HCC incidence have been reported from several Western countries, including France, Australia, and the United States, mainly because of the rising incidence of HCV (McClune & Tong, 2010). At least one million new cases of HCC occur annually and mortality from this disease remains high (Munoz et al., 1988; Rustgi, 1987; Simonnetti et al., 1991). Surgery, including hepatectomy and transplantation, remains the main curative strategy for hepatocellular carcinoma. The history of hepatic surgery is strongly involved with the history of use of bleeding-control during hepatic operations. In the early 1900s a small but significant step forward was made in liver surgery by J. Hogarth Pringle, who in 1908 described a method for digital compression of the hilar vessels to control hepatic bleeding from traumatic injuries. Credit for the first anatomic liver resection is usually given to Lortat- Jacob, who performed a right hepatectomy in 1952 in France. Wang Chen En in 1961 was first to report a successful hepatic resection for liver cancer in China.

Blood loss during liver resection is one of the most important factors affecting the perioperative outcomes of patients undergoing liver resection. It has been accepted that intraoperative blood transfusion is a risk factor for tumor recurrence, and that infiltrative tumor type, surgical margin <10 mm and intraoperative blood transfusion are independent prognostic factors for overall survival.

1.1 Background

Blood transfusion has been found to be a highly significant factor which influences outcome of hepatectomy, and major bleeding and major blood transfusion during major hepatectomy are of especial importance.
The long-term survival of patients with hepatocellular carcinoma after hepatectomy depends on tumor staging, hepatic functional reserve before operation and history of blood transfusion. Preventing major intraoperative bleeding and avoiding allogeneic blood transfusion can significantly improve the disease free and overall survival rates in HCC patients. Rui et al., reported (Rui et al.; 2004) that major hepatectomy without allogeneic blood transfusion can reduce postoperative morbidity and recurrence rate of patients with HCC.

1.2 Selection of patients for right-trisectionectomy of huge liver tumor

Up to now, treatment of huge liver cancers is still very difficulty due to poor outcomes and higher mortality and morbidity (Hanazaki et al, 2001; Regimbeau et al, 1999). Since the middle of last century the right trisectonectomy (previous trisegmentectomy) has been used for huge hepatic neoplasms which involve the right and left medial sections of the liver (Quattlebaum 1953). Starzl described and clearly defined in detail a safe technique for right trisectionectomy (Starzl et al 1975). Most reports have indicated that right trisectionectomy is effective for extensive hepatic malignancy, based on patients who have had long-term survival after this operation (Sugiura et al., 1994; Yamamoto et al 1995). Rui reported on a retrospective series of patients in which thirty three cases of right trisectionectomy were all performed under normothermic interruption of the porta hepatis at single time for huge primary liver cancer. The 1-, 3- and 5- year survival rates after right trisectionectomy were 71.9%, 40.6% and 34.4%, respectively. Among the 33 cases of right trisectionectomy, 2 cases did not utilize allogeneic blood transfusion and had good recoveries (Rui et al., 2003). Up to now, the longest cancer free survival in our series is 23 years. This patient is still alive in Beijing.

The feasibility of right trisectionectomy for a given patient must be carefully evaluated according to the following criteria: (1). Tumor(s) (including less than 2 satellite nodules) limited to the right lobe and left medial portion of the liver. There must be no evidence of cancer invasion in the left lateral segment; (2). Tumor mass must have clear borders or a pseudocapsule, and there must be no tumor thrombus in the trunk of the portal vein and hepatic vein, but liver resection remains the only therapeutic option that may offer a chance of cure for HCC with PVTT (Lau WY et al 2008). There were 17 cases (51.5%) with tumor thrombi in the right branch of the portal vein in our right trisectionectomy patients (Rui JA et al 2003). (3). There must be no evidence of distant metastasis; (4). Compensatory enlargement of the left lateral section should be obvious; (5). The Child-Pugh classification of liver function must be “A” and the indocyanine green retention rate (ICGR 15) at 15 minutes should be lower than 15 % before surgery; (6). During the Child-Pugh classification of liver function is “A” and ICGR is less than 15%, the remnant liver volume can be at least 25% of whole liver. The CT volumetry can be utilized to determine the liver and tumor volume before surgery (Mandli et al 2008).

2. Surgical technology for major hepatectomy without allogenic blood transfusion

Major hepatectomy has recently been defined as a resection of four or more liver segments (Reddy et al., 2011) which differs from the former definition of “resection of three liver
Control of hemorrhage is the key factor in liver resection for HCC. Blood loss of more than 1000 ml is defined as major bleeding. In patients with risk factors for bleeding, it is necessary to take effective steps in order to minimize intraoperative blood loss in hepatectomy for patients with HCC, so that allogeneic blood transfusion can be avoided. Surgeons play an important role in avoiding allogeneic blood transfusion and thus improving the prognosis of these patients. Rui performs major hepatectomy without allogeneic blood transfusion via a number of surgical techniques, including normothermic interruption of the porta hepatis at a single time and application of supplementary instruments. Moreover, the surgical procedures characterized by single time interruption of the porta hepatis for major hepatectomy, including right trisectionectomy have been used in more than thirty county and town hospitals located in thirteen provinces in China and have been demonstrated to be feasible and successful.

2.1 Surgical procedures characterized by single time interruption of the porta hepatis is requisite for major hepatectomy without allogeneic blood transfusion

Foster said: “Surgical technique is an art form. It can be very personal, based mostly on experience, or it can take a cookbook approach. For many standard operations, we follow in the ruts created by our teachers, perhaps adding a nuance or two called forth by an unusual situation or by a creative mind. Unfortunately, many years ago when I needed help, there was no available to teach me to operate on the liver.” (Foster, 1989).

179 cases of hepatectomy for huge HCC were performed in our hospital from January 1995 to December 2002. Among these patients, 155 (86.6%) cases were males and 24 (13.4%) females, with ages ranging from 15 to 77 years (mean ± SD, 56.3 ± 13.7 years). 138 (77.1%) were hepatitis B surface antigen (HBsAg) positive and 144 (80.4%) had liver cirrhosis. 165 patients (92.2%) were evaluated as grade A and 14 (7.8%) were grade B in the Child-Pugh’s classification prior to surgery. Tumor sizes ranged from 5 to 30 cm (mean ± SD, 7.9 ± 4.6 cm). Serum alpha-fetoprotein (AFP) in 63 patients (35.2%) was higher than 400 ng/ml and 75 patients were TNM stage II, 60 were stage III, 37 were stage IVa, and 7 were stage IVb. These hepatectomies were all performed under single time normothermic interruption of the porta hepatis. Interruption of flow through the porta hepatis lasted 15 to 40 minutes (mean ± SD, 25.3 ± 6.8 minutes). The ultrasonic dissector (CUSA System 200) was applied for dissecting hepatic parenchyma. These hepatectomy procedures included right trisectionectomy in 23 patients, left trisectionectomy in 4 patients, extended right hepatectomy in 11 patients, extended left hepatectomy in 3 patients, central hepatectomy in 4, right hepatectomy in 30, and left hepatectomy in 14 patients. The postoperative complication rate was 10.6% (19/179), and operative mortality was 1.1%. Postoperatively, overall and cancer-free survival rates at 1, 2, 3, 4 and 5 years were 82.0%, 56.7%, 51.1%, 46.2% and 40.2%; and 73.1%, 53.2%, 46.0%, 44.5% and 38.1%, respectively (Zhou et al., 2007). These results demonstrate that hepatectomy applying normothermic continuous single interruption of the porta hepatis, but not intermittent multiple occlusions of hepatic inflow is safe and tolerable for selected patients with HCC including many who also have cirrhosis.
At the same time, no damage to the liver has been found by either the electron microscopic examination of liver tissue biopsies or by liver function tests within 20 minutes of single time normothermic interruption of the porta hepatis. Our clinical practice has shown that a single time 20-42 minute normothermic interruption of the porta hepatis is safe with use of skilled surgical technique. Since 1984 we have applied single time normothermic interruption of the porta hepatis for all surgical hepatectomy procedures. We have carried out one hundred cases of hepatic resection without mortality under single time normothermic interruption of the porta hepatic in a period of 4 years (1984-1988), and our subsequent surgical mortality has been shown to be less than 1.3%.

Diminished bleeding by applying single time interruption of porta hepatis serves to avoid allogeneic blood transfusion during liver resection. We have conducted a retrospectively study of 51 patients who received hepatectomy without allogeneic blood transfusion. Of these patients whose ages ranged from 24 to 77 years (mean 46.5 years), 40 were men and 11 were women. Clinical diagnosis showed primary liver cancer in 29 patients, metastatic liver cancer in 6, hepatic hemangioma in 10, and benign hyperplasia in 6. TNM staging of the primary liver cancer showed 15 patients were stage II (51.8%), 10 patients were stage III (34.5%), and 4 were stage IVa. The mean tumor diameter was 8.7 cm (range 6.5 to 18 cm). Preoperative Child-Pugh classification for liver function was grade A in 34 patients (66.7%) and grade B in 17 (33.3%). Surgical procedures included right trisectionectomy in 2 patients (3.9%), right lobectomy in 6 (11.8%), left lobectomy in 7 (13.7%), medial hepatectomy in 3 (5.9%), and trisegmentectomy in 33 (64.7%). The mean operative time was 181 minutes (range 90 to 300 minutes). Single time normothermic interruption of the porta hepatis was applied in all procedures, with a mean interruption time of 16 minutes (range 8 to 35 minutes). The ultrasound dissector (CUSA System 200) was used for dissecting parenchyma of the liver, and intraoperative ultrasonography was used for localization of tumors. The mean blood loss was 755ml (range 400 to 2000 ml). Thirty-two patients (63.0%) accepted autologous blood transfusion (mean volume, 326 ml; range 200 to 600 ml). Pathologic examination showed hepatocellular carcinoma in 27 patients, mixed hepatocellular-cholangiocarcinoma in 2, liver metastasis of malignancies from colorectal cancer in 6 patients, hepatic cavernous hemangioma in 10 patients, and hepatic focal nodular hyperplasia in 6. At the same time there were 60 patients in the control group who received hepatectomy with allogeneic blood transfusion, including 48 cases of primary liver cancer. Blood was transfused routinely if the haemoglobin level fell to < 8g/dl. Fresh frozen plasma was transfused if the prothrombin time rose to >30s. As a result the operative mortality and morbidity rates in the study group (without allogeneic blood transfusion) were 0%, and 9.8% respectively, while in the control group (allogeneic blood transfusion) mortality and morbidity were 3.3% and 28.3%, respectively. Cancer recurrence within three years was discovered in 9 of 51 patients in the study group. The 1, 2 and 3 year cancer recurrence rates in the study group were 24.1%, 27.6%, and 31.0%, respectively; while in the control group 27 of 46 patients had tumor recurrence in the same period, and the 1, 2 and 3 year recurrence rates were 43.5%, 54.3% and 58.7%, respectively. Significant differences (p < 0.05) were present between these two groups (Rui et al., 2004) demonstrating the advantages of major hepatectomy applying single interruption of porta hepatis without allogeneic blood transfusion.
2.2 Application of supplementary instruments

2.2.1 Intraoperative ultrasound

Intraoperative ultrasonography (US) of the liver provides the surgeon with useful real-time diagnostic and staging information that may result in an alteration of the planned surgical approach. Current applications for intraoperative US of the liver include evaluation of tumor staging and metastatic survey, guidance for metasasectomy and various tumor ablation procedures, documentation of vessel patency, evaluation of intrahepatic biliary disease, and guidance for whole-organ or split-liver transplantation. To obtain the most useful information with intraoperative US, the sonographer must use a dedicated transducer and a scanning method appropriate for the purpose of the examination. Motohide applied 3D-US in 24 patients undergoing hepatic resection, and found that this technique allowed easy visualization of the tumors and vascular anatomy. It is thus considered to be an efficient and safe navigation system in liver surgery (Motohide et al., 1998). In addition, application of intraoperative US of the liver with current transducer resolution permits the identification of lesions larger than 2 mm. Sensitivity of more than 90% has been documented for detection of lesions in the liver, with positive and negative predictive values of 90% and 78%, respectively (Guimaraes et al., 2004). Since 1983, we have utilized intraoperative ultrasonography of the liver for patients with liver tumors. The sensitivity is more than 90% in our series which is consistent with what reported by Zacherl (2002).

2.2.2 Ultrasound dissector for dissecting parenchyma of the liver

Since November 1992 we have applied the ultrasonic dissector (CUSA system 200) for dissecting hepatic parenchyma, instead of using the previous finger fracture technique. Combined application of single time interruption of the porta hepatis and ultrasonic dissector can reduce intraoperative bleeding in liver resection. The advantages of applying this technique are: (1) It can reveal small vessels and segments of the biliary tree which are less than 2mm; (2) It allows damage to the portal vein and hepatic vein to be diminished resulting in less blood loss; (3) It promotes quick portal hepatic dissection and tumor resection. However, the disadvantage may be prolongation of operating time.

Fan reported that they performed major hepatectomy in 69 patients with the assistent of the ultrasonic dissector, and found that it is better than the crushing clamp and finger fracture technique in hepatocellular carcinoma (Fan et al., 1996).

2.2.3 RF (radiofrequency) assisted liver resection technique

Milicevic et al reported that the sequential coagulate-cut, RF-assisted liver resection technique is a safe liver transection technique associated with minimal blood loss and it has facilitated tissue-sparing liver resection (Milicevic et al., 2007). Navarra reported RF-assisted liver resection (Navarra et al., 2004), in which the median resection time was 47.5 minutes (range 30-110) with median blood loss of 30 mls (range 15-992) and mean pre-operative and post-operative hemaglobin values of 13.5 g/dL (SD ± 1.7) and 11.6 g/dL (SD ± 1.4) respectively. No blood transfusion was registered, nor was any mortality observed. There was one post-operative complication which was a sub-phrenic abscess. The median post-
operative stay was 8 days (range 5-86). Long reported: Over the past few years, a new technique for liver resection assisted with radiofrequency has been developed at the author’s hospital, expanding the role of radiofrequency in liver surgery from mere tumor ablation to routine hepatic resection (Long R Jiao et al 2008). Ayav concluded that major hepatectomy using RF can decrease the rates of blood transfusion, postoperative liver failure, ICU admission, and postoperative stay. Moreover the price is significantly lower as compared to total vascular exclusion (Ayav et al., 2007).

3. Advantages from single time interruption of the portal hepatis without allogeneic blood transfusion in hepatectomy

3.1 Advantages from single time interruption of the porta hepatis

Since there is a lack of donors for liver transplantation, liver resection continues to be the first choice for patients with resectable hepatocellular carcinoma with liver cirrhosis but compensated liver function. Univariate analysis has shown that the presence of portal vein tumor thrombosis and satellite nodules, high TNM stage, high Edmondson-Steiner grading, and blood transfusion are all associated with worsened prognosis (Zhou et al., 2007).

In a period of 8 years (from January 1995 to 2002) we successfully performed major hepatectomy in 81 patients with HCC combined with cirrhosis applying normothermic continuously single interruption of the porta hepatis. The mortality and morbidity rates were 1.2% and 24.7% respectively, indicating that the procedure can be carried out safely. Less blood loss and shorter operating time have been achieved in our cohort.

The significance of intermittent hepatic inflow occlusion for safe hepatectomy has been generally recognized (Man et al., 2003). Some surgeons have argued that intermittent interruption of flow through the porta hepatis leads to less liver injury during hepatic resection than with continuous flow interruption (Belghiti et al., 1999). Belghiti and Pol reported that the mean ischemic time under intermittent interruption of flow through the porta hepatis for hepatectomy was approximately 40 min (Belghiti et al., 1999; Pol et al., 1999), which is far longer than the mean ischemic time of 20.6 min that we reported with a single interruption of the porta hepatic for major hepatectomy. Our experience is similar to results of a recent prospective, randomized clinical trial from Italy (Capussotti et al., 2003). It is established that major hepatectomy under normothermic continuous interruption of flow through the porta hepatis is well tolerated by HCC patients, including those with liver cirrhosis, when the interruption time was well controlled. Thus, intermittent interruption of the porta hepatis may not be necessary (Zhou et al., 2007). It is easily understood that compared with intermittent multi hepatic inflow occlusions, continuous single interruption can simplify procedures, shorten operating time, and reduce blood loss, especially during transaction of liver parenchyma.

It is well known that reperfusion injury following ischemia is a clinically important process that contributes significantly to tissue damage (Mitchell & Cotran, 2003). Single time interruption of the porta hepatis during liver resection not only diminishes blood loss, but also attenuates reperfusion injury following ischemia as compared with multi-interruption of the porta hepatis.
3.2 Advantages of avoiding allogeneic blood transfusion

We have successfully performed major hepatectomy applying single time normothermic interruption of the porta hepatis in 51 patients without allogeneic blood transfusion, and have effectively limited intraoperative bleeding. It is evident that postoperative complications of major hepatectomy can be markedly reduced, recurrence rate can be decreased, and mortality can be decreased by avoiding allogeneic blood transfusion. Our results confirmed the conclusion that perioperative allogeneic blood transfusion is responsible for a relatively poor prognosis.

Poon reported that in a prospective study of 377 patients over 10 years, absence of perioperative transfusion is an independent favorable prognostic factor for disease-free survival, and improves survival results after resection for HCC (Poon et al., 2001).

3.3 Immunomodulation and blood transfusion

It is known that allogeneic blood transfusion-associated immunomodulation has been associated with alterations in immune function in transfusion recipients, including decreased ratio of helper T-lymphocytes to suppressor T-lymphocytes, attenuated function of natural killer cells, defective antigen presentation, and reduction in cell-mediated immunity (Blajchman, 2002). Perioperative allogeneic blood transfusion may play an important role in suppressing the host immune system, for example by decreasing natural killer cell activity (Hanna et al., 1980; Herberman, 1984) and/or increasing suppressor T-cell activity and inhibition of lymphocyte transformation, thereby diminishing specific and non-specific immune responses. These effects are possibly due to the cytological and immunological factors for tumor recurrence after blood transfusion allowing for progression of residual cancer and leading to a poor prognosis (Kaplan et al., 1984). Therefore, it is suggested that avoiding intraoperative and perioperative allogeneic blood transfusion is beneficial to patients with resectable HCC, particularly to those with large tumors (Rui et al., 2004; Sugita et al., 2007). For a better prognosis including prevention of recurrence and metastasis, and prolongation of survival time, the surgeon must master skilled surgical techniques, and apply suitable surgical procedures and supplementary instruments for hepatectomy, especially for major hepatectomies. In summary, hepatectomy without allogeneic blood transfusion is advantageous to diminishing surgical complications and improving the prognosis of HCC patients (Kaplan et al., 1984; Rui et al., 2004).

4. Case report

Case 1: A 15 years old boy was diagnosed with hepatocellular carcinoma, and a right trisectionectomy was performed with single time interruption of the porta hepatis. The resected tumor weighted 2000 gm (Figure1). The postoperative cancer free survival time was 6 years and the patient died of non-neoplastic disease.

Case 2: A 57 years old woman was diagnosed with hepatocellular carcinoma, and a right trisectionectomy was performed with single time interruption of the porta hepatic in 1988. The resected tumor weighted 2200gm (Figure2). She is still alive in Beijing 23 years after right trisectionectomy without recurrence.
Fig. 1. The resected tumor tumor weighted 2000 gm from a 15 years old boy. This patient was operated for right trisectionectomy under single time interruption of the porta hepatis, and postoperative cancer free survival for 6 years, died of noncancerous disease.

Fig. 2. The resected tumor weighted 2200gm with a diameter of 15X18cm from a 57 years old woman. This patient was operated for right trisectionectomy under single time interruption of the porta hepatis in 1988 and is still alive in Beijing 23 years after right trisectionectomy.

Case 3: A 24 years old man was diagnosed with hepatocellular carcinoma. A right trisectionectomy was performed under single time interruption of the porta hepatis, loss blood of intraoperation 1500ml, accepted autologous blood transfusion 600ml, without allogeneic blood transfution. The resected tumor weighted 2500 gm (Figure3). The patient was discharged from hospital after recovery at 32 days after operation.
Fig. 3. The resected tumor weighted 2500gm with a diameter of 17.5X13.7cm from a 24 years old man. This patient was operated for right trisectionectomy under single time interruption of the porta hepatis without allogeneic blood transfusion and discharged from hospital after recovery at 32 days after operation. The pathologic diagnosis was hepatocellular carcinoma.

5. References


www.intechopen.com
This book covers the clinical aspects of hepatocellular carcinoma. This book is a compendium of papers written by experts from different parts of the world to present the most up-to-date knowledge on the clinical aspects of hepatocellular carcinoma. This book is divided into three sections: (I) Diagnosis / Differential Diagnosis; (II) Surgical Treatment; (III) Non-surgical Treatment. There are 19 chapters covering topics from novel diagnostic methods to hepatic lesions mimicking hepatocellular carcinoma, from laparoscopic liver resection to major hepatectomy without allogeneic blood transfusion, from molecular targeted therapy to transarterial radioembolization, and from local ablative therapy to regional therapy. This volume is an important contribution to the clinical management of patients with hepatocellular carcinoma. The intended readers of this book are clinicians who are interested in hepatocellular carcinoma, including hepatologists, liver surgeons, interventional and diagnostic radiologists, pathologists and epidemiologists. General surgeons, general physicians, trainees, hospital administrators, and instruments and drug manufacturers will also find this book useful as a reference.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: